0 365

Cited 9 times in

Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes

Authors
 Yundeok Kim  ;  In Ho Kim  ;  Hyeong Joon Kim  ;  Silvia Park  ;  Kyoo Hyung Lee  ;  Soo Jeong Kim  ;  Jung Hee Lee  ;  Dae Young Kim  ;  Sung Soo Yoon  ;  Yeo Keoung Kim  ;  Jun Ho Jang  ;  Seon Yang Park  ;  Jae Sook Ahn  ;  Chul Won Cheong  ;  Je Hwan Lee  ;  June Won Cheong  ;  Korean Society of Hematology Acute myeloid Leukemia/Myelodysplastic Syndrome Working Party 
Citation
 INTERNATIONAL JOURNAL OF HEMATOLOGY, Vol.99(5) : 635-643, 2014 
Journal Title
 INTERNATIONAL JOURNAL OF HEMATOLOGY 
ISSN
 0925-5710 
Issue Date
2014
MeSH
Adolescent ; Adult ; Aged ; Antimetabolites, Antineoplastic/therapeutic use* ; Azacitidine/therapeutic use* ; DNA (Cytosine-5-)-Methyltransferases/antagonists & inhibitors* ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Male ; Middle Aged ; Myelodysplastic Syndromes/diagnosis ; Myelodysplastic Syndromes/drug therapy* ; Myelodysplastic Syndromes/mortality ; Myelodysplastic Syndromes/therapy ; Preoperative Care ; Retrospective Studies ; Transplantation, Homologous ; Treatment Outcome ; Young Adult
Keywords
Myelodysplastic syndrome ; Hypomethylating agent ; AlloSCT
Abstract
Allogeneic hematopoietic stem cell transplantation (alloSCT) is currently the only curative treatment modality for myelodysplastic syndromes (MDS). The treatment paradigm for MDS has changed in recent years with the introduction of hypomethylating agents (HMAs). The present retrospective multicenter study was designed to assess the effects of pre-transplant HMA on transplant outcome and determine which patients would benefit most from this therapy. A total of 109 patients who received alloSCT at one of five institutions between 2007 and 2010 were enrolled in this study regardless of pre-transplant HMA therapy. 81 of the 109 patients enrolled were treated with HMA prior to alloSCT. 28 patients received alloSCT without HMA bridging. The distributions of WHO classification groups and IPSS scores were similar between the two groups (P = 0.752 and P = 0.265, respectively). Pre-transplant HMA did not affect OS (P = 0.244), and there were no differences in response to HMA therapy within the HMA-treated group. The cumulative incidence of NRM was not significantly different between the two groups (P = 0.500). However, for patients with a high blast count (>5 % of bone marrow at the time of diagnosis), pre-transplant HMA therapy had a NRM benefit (83.3 vs. 48.6 %, P = 0.014).
Full Text
http://link.springer.com/article/10.1007/s12185-014-1549-3
DOI
10.1007/s12185-014-1549-3
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Soo Jeong(김수정) ORCID logo https://orcid.org/0000-0001-8859-3573
Kim, Yun Deok(김윤덕) ORCID logo https://orcid.org/0000-0002-5336-7936
Cheong, June-Won(정준원) ORCID logo https://orcid.org/0000-0002-1744-0921
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/138641
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links